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Abstract
Background: The tumor-specific microregional effects of the anticancer agent RRx-001, a novel epigenetic-based
radio/chemosensitizer with nitrogen oxide-donating properties in phase II clinical trials, were investigated with
whole tissue section quantitative immunohistological staining in mouse SCCVII and human U87 tumors.
Results: SCCVII tumors exhibited regions of intermittent perfusion exemplified by co-localization of vessels with the
hypoxia marker pimonidazole commonly occurring throughout the tissue. A moderate increase in perfusion (21 to
28 %) was observed after a bolus dose of the perivascular stain DiOC7(3), however, with the absence of an increase
in tissue oxygenation. U87 tumors showed an absence of blood flow over large areas of treated tumors after
dosing with RRx-001. However, these areas did not become necrotic and returned to near normal levels after 12 h.
No significant change in tumor hypoxia was seen at 90 min or 12 h. For both tumor types, RRx-001 treatment
resulted in the loss of perfusion in the large regions of the tumor; however, at the 12-h time point, both tumor
types showed an increase in vessel perfusion but no significant decrease in hypoxia.
Conclusions: These data suggest a redistribution of blood flow within the tumor for both tumor types akin to
vascular normalization. Differences between the tumors were related to tumor architecture and distribution of
alpha-smooth muscle actin (α-SMA). RRx-001 shows promise for short-term blood flow redistribution in tumors
with a pericyte- and α-SMA-rich vasculature. Expression of α-SMA in tumor vasculature could therefore be
useful for predicting tumor response to RRx-001.
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Background
The tumor microenvironment has been compared to
a neighborhood [1]. In such an analogy, the “slums”
represented by the poorly perfused, marginalized, nec-
rotic center of the tumor could be contrasted with
the better-differentiated “suburbia” of the periphery
with a transition zone in between them. However,
equating the periphery with high status and centrality
with low status is oversimplified given the diversified
pattern of “hot spots” of hypoxia and perfusion
throughout the core of the tumor due to variations in
vasculature development [2]. These “pockets of decay”
in the tumor based on the mismatched forces of
supply and demand have led to supply side antiangio-
genic/antivascular strategies to push these hypoxic
areas to the tipping point of eradication. However,
efforts at eradication inevitably meet with difficulty
and/or failure because their insularity in the tumor
microenvironment transforms them into “fortresses”
that are difficult for chemotherapy to penetrate.
The tumor microenvironment is a catch-all term to
denote a “local” set of “neighborhood” conditions,
which includes hypoxia status and the architecture of
the vasculature. The hallmark of the microenviron-
ment is heterogeneity with thinly divided, cheek-by-
jowl zones of wealth and poverty in terms of blood
flow and oxygenation. The driver of this heterogeneity
is hypoxia-induced neovasculogenesis and metastatic
dissemination, which arguably is secondary to the
maturity of the vasculature. Two main categories of
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hypoxia are present in tumors: chronic hypoxia, also
known as diffusion-limited or permanent hypoxia,
and acute hypoxia, also known as perfusion-limited
or transient hypoxia [3].
Vasodilator-unresponsive microvessels devoid of smooth
muscle actin coverage are prone to intermittent col-
lapse or compression, leading to acute or transient
hypoxia. Acutely induced hypoxic stress may enhance
the potential metastatic efficiency of the tumor to a
greater degree than prolonged exposure to hypoxia
since transiently hypoxic cells have the advantage of
proximity to functional blood vessels and a higher
energy status than chronically hypoxic cells [4].
Given the nocivity of acute hypoxia, in terms of its
role in tumor aggressiveness, an alternative strategy
to the hypoxia-exacerbating effects of antiangiogenesis
is a redistribution of the blood supply from immature
vessels, where blood flow is already sluggish or stag-
nant, to more mature blood vessels, thereby normaliz-
ing blood flow.
RRx-001, a novel investigative anticancer agent, cur-
rently under investigation in multiple phase II trials,
binds to hemoglobin and influences the rheology of red
blood cells, which bind to hypoxic tumor endothelium,
leading to a global redistribution of blood flow [5]. In
light of these pharmacokinetic and pharmacodynamic
properties, we studied the vascular hemodynamics of
RRx-001 and the angioarchitectural features of the
murine syngeneic SCCVII tumor and the human gli-
oma xenograft, U87, pre- and post-RRx-001 dose, to
determine possible differences in vascular responsive-
ness and define the spatial variations in intratumoral
blood flow (Fig. 1).
Results and discussion
The microregional effects of RRx-001 on tumor blood
flow and oxygenation were examined in vivo by map-
ping drug effects with respect to the microvascular
architecture of mouse SCCVII and human U87 tumor
cryosections using whole tissue mapping and multi-
plexed immunostaining techniques [6]. Combinations
of markers including pimonidazole, CD31, DiOC7(3),
5-bromo-2-deoxyuridine, and HIF1-α were mapped on
the tumor sections. A single dose of 15 mg/kg of
RRx-001 was administered IV to C3H mice bearing
SCCVII tumors and to SCID mice bearing U87 tumors.
The tumors were excised 90 min and 12 h post dose
then weighed and immediately frozen. Images of
multiple-stained cryosections were obtained to provide
microregional information on the relative position of
proliferating cells, areas of hypoxia, perfusion, and
vasculature after treatment (Fig. 2), and, using ad-
vanced imaging, key parameters were calculated from
images of entire tumor sections.
Vascular dysfunction was observed in a large propor-
tion of both U87 and SCCVII tumors. SCCVII tumors
exhibited regions of intermittent perfusion exemplified
by co-localization of vessels with the hypoxia marker
pimonidazole commonly occurring throughout the
tissue (Fig. 3). Only 21 % of the vessels showed perfu-
sion after a bolus dose of the perivascular stain
DiOC7(3) (Fig. 4), increasing to 28 % 12 h post-RRx-
001 (p < 0.05). Paradoxically, an increase in tissue oxy-
genation was not seen while modestly increased,
though not statistically significant, pimonidazole bind-
ing was observed (Fig. 5). The percent of tissue that
stained positive for HIF1-α was found to decrease
after 90 min and 12 h (Fig. 6, p < 0.05 for post 12 h).
In U87 tumors, a dramatic decrease in perfusion in
the centrally located tumor vessels was observed
90 min post-RRx-001 treatment (Fig. 7). Blood flow
over large areas of treated tumors was completely shut
down, leaving a rim of functional vessels around the
periphery of the tumor and increasing the overall
level of hypoxia during that time period. The area of
vascular shutdown stained positive for CD31 and tis-
sue did not appear necrotic. Figure 8 shows the per-
cent of vessels that were found to be positive for the
perfusion marker DiOC7 and tracks individual vessels.
In contrast, Fig. 9 quantitates “gross” tissue shutdown
by area. Analysis for perfusion, though not statistically
significant, indicated that less than 20 % of the vessels
showed perfusion after a bolus dose of the perivascular
stain DiOC7(3) (Fig. 8), increasing to approximately
28 % 12-h post-RRx-001. These results were consistent
with findings from the SCCVII tumors (Fig. 4). The
observed decrease in perfused vessels translated to an
increase in unperfused tissue as shown in Fig. 9. While
changes in perfusion were noted, there was no significant
change in the fraction of necrosis at 90 min and 12 h,
suggesting that the large, statistically significant (p < 0.05),
unperfused regions seen at 90 min had recovered rather
Fig. 1 Chemical structure of RRx-001 (1-bromoacetyl-3,3-dinitroazetidine)
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Fig. 2 Immunohistochemistry study design. ABDNAZ = RRx-001
Ctrl (#4) 
1 mm
ABDNAZ 15mg/kg i.v. 
wait 90 min (#10) 
ABDNAZ 15mg/kg i.v. 
wait 12 hours (#16) 
150 µm
Ctr  (#4)
ABDNAZ 90 min (#10)
blood flow  (DiOC )
hypoxia (pimonidazole)
vasculature (CD31)
blood flow  (DiOC )
proliferation (BrdUrd)
vasculature (CD31)
HIF1-
ABDNAZ 12 hours (#16)
a b
)
Fig. 3 a Effect of RRx-001 (ABDNAZ) treatment on blood flow and tissue hypoxia in SCCVII tumors. b Comparison of RRx-001 (ABDNAZ) effect on
tumor architecture, blood flow, hypoxia, and HIF1-α status in SCCVII tumors
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than become necrotic (Fig. 9). No significant change in
tumor hypoxia was seen at 90 min or 12 h (Fig. 10).
For both tumor types, RRx-001 appeared to cause
the loss of perfusion in the large regions of the
tumor; however, at the 12-h time point, both tumor
types showed an increase in vessel perfusion but no
overall decrease in hypoxia: Indeed, while overall
changes in perfusion and hypoxia are mild, local
changes within the tumor were found to be dramatic.
In contrast to previous work that demonstrated
increases in RRx-001-mediated bulk tumor blood flow
in SCCVII tumors by contrast-enhanced ultrasound
(CEUS) [7], these data suggest a redistribution of blood
flow in both tumor types while differences between
the tumors were related to tumor architecture and
distribution of alpha-smooth muscle actin (α-SMA).
Conclusions
In the rhetoric of urban space, the tumor microenvir-
onment is a heterogeneous yet integrated co-op neigh-
borhood etched with boundaries and borderlands that
intersect, overlap, collide, and coexist along lines drawn
and redrawn by quirks of intricate capillary network
geometries, leading to the heterogeneity of oxygen
delivery and the associated oxygen gradients.
The areas with the greatest metastatic potential may
not be the down-and-out “skid row” population of
chronically ischemic cells but the still-viable population of
acutely hypoxic cells proximate to a mature vascular
network and transiently enriched with oxygen.
Antiangiogenic or antivascular strategies that inhibit
the existing or the neovasculature may only serve to
increase the hypoxic fraction and, thus, the meta-
static efficiency of the tumor.
In contrast, the antitumor and antiproliferative effects
of the novel epigenetic inhibitor, RRx-001, may be
ascribed to a relative change or reorganization of blood
Fig. 4 Percent of vessels positive in SCCVII tumors for the perfusion
marker DiOC7(3). Error bars depict ±SD, N = 6 for each group, p < 0.05
between control and 12 h
Fig. 5 Extent of hypoxia by average tissue pimonidazole intensity
staining for SCCVII tumors. Error bars depict ±SD, N = 6 for each
group (not statistically significant)
Fig. 6 Percent tissue HIF1-α positive in SCCVII tumors. Error bars
depict ±SD, N = 6 for each group (p < 0.05 between control and 12 h)
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flow within the tumor. This conclusion is supported by
the macroscopic appearance of poorly perfused and
hypometabolic areas in the SCCVII and U87 tumors
without an increase in the overall hypoxic fraction post-
RRx-001 treatment.
RRx-001-modified red blood cells selectively home to
and obstruct morphologically immature and hypoxic
tumor vessels, leading to a compensatory redistribution
of blood flow through more mature smooth muscle
pericyte-covered vessels, akin to vascular normalization.
This normalization, which has been demonstrated
preclinically and clinically, improves the delivery of
cytotoxic chemotherapy and radiosensitizing oxygen, im-
proving tumor control.
SCCVII tumors are characterized by a more mature
angioarchitecture than U87 xenografts. The hypothesized
effect of RRx-001 on SCCVII tumors is a multifocal,
diffuse vasoconstriction with a uniform redistribution of
blood flow in contrast to the focally vasoconstricted
U87 tumors with moth-eaten cell-lucent areas.
Although contrast-enhanced ultrasound detected
changes in bulk tumor blood flow in SCCVII tumors
after RRx-001 administration suggesting a provascu-
lar effect [8], the data presented herein demonstrate
a significant but temporary loss of perfusion with no
significant concomitant change in the level of hypoxia,
Ctrl (#19) 
1 mm
)
ABDNAZ 15mg/kg i.v. 
wait 90 min (#12) 
ABDNAZ 15mg/kg i.v. 
wait 12 hours (#17) 
150 µm
Ctr  (#19)
ABDNAZ 90 min (#12)
blood flow  (DiOC )
hypoxia (pimonidazole)
vasculature (CD31)
blood flow  (DiOC )
hypoxia (pimonidazole)
proliferation (BrdUrd)
ABDNAZ 12 hours (#17)
a b
Fig. 7 a Effect of RRx-001 (ABDNAZ) treatment on blood flow and tissue hypoxia in U87 tumors. b Comparison of RRx-001 effect on
tumor architecture, blood flow, and hypoxia in U87 tumor
Fig. 8 Percent of vessels positive in U87 tumors for the perfusion
marker DiOC7(3). Error bars depict ± SD, N = 6 for each group (not
statistically significant)
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suggesting a redistribution of blood flow within the
tumor. Differences in the local nature of the effect
between the two tumor types can be attributed to
tumor architecture.
The binary view of pharmacologic blood flow modu-
lation as either pro- or antivascular should be amended
to include strategies of redistribution [9]. Just like the
rehabilitation of “low rent” neighborhoods charac-
terized by overcrowding and marginalization, the redis-
tributive strategy posits that the marginal, acutely
hypoxic regions of the tumor can be revitalized or nor-
malized instead of demolished, thereby reducing the
oxygen asymmetry and the hypoxic potential for angio-
genesis and metastatic dissemination.
The tumor microenvironment should not be viewed
as homogenous masses of cancer cells but rather mix-
tures of cell populations with varying levels of hetero-
geneity that respond differently to different vascular
modification strategies. Diagnostic imaging and histo-
pathologic examination in the setting of vascular
normalization open a window to the particular struc-
tural and biochemical characteristics of each tumor
for treatment optimization and improved patient
outcomes.
Methods
Materials
RRx-001 used in these studies was obtained from
EpicentRx, Inc. RRx-001 is a cyclic nitro compound
with molecular formula of C5H6BrN3O5, molecular
weight of 268.02, and chemical structure depicted in
Fig. 1. The synthesis and characterization of RRx-
001 is reported in detail elsewhere [10].
Ethics
The methods in this study were carried out in accord-
ance with approved guidelines (including ARRIVE and
the Canadian Council on Animal Care guidelines) and
the relevant institutional review boards (IRB) at the
University of California San Diego (UCSD), and British
Columbia Cancer Research Centre approved the ex-
perimental protocols.
Mice and tumors
Female C3H/Hen mice and female NOD.CB17-
Prkdcscid/J mice were bred and maintained in the
British Columbia Cancer Research Centre animal facility
in accordance with the Canadian Council on Animal
Care guidelines. The mice were allowed free access to
standard laboratory rodent food and water. Tumor
cells (SCCVII: 0.5 × 106 cells in 50 μL; U87: 5 × 106
cells in 50 μL) were implanted sub-cutaneously into
the sacral region. The mice were administered RRx-
001, 15 mg/kg IV, in a single dose when tumors
Fig. 10 Tumor hypoxia in U87 tumors by average tissue pimonidazole
intensity staining. Error bars depict ±SD, N = 6 for each group (not
statistically significant)
Fig. 9 Percent tissue area exhibiting gross vascular shutdown. Regions
of shutdown and necrosis were identified as a fraction of whole tissue
area. Percent tumor area in U87 tumors that is necrotic (blue square) or
unperfused (red square). Error bars depict ±SD, N = 6 for each group
(p < 0.05 between control and 90 min for unperfused area, other data
not significant)
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reached ~150 mm3 as calculated from caliper meas-
urement of three orthogonal diameters (a, b, c) using
the formula volume = π/6(abc). Each arm of an experi-
ment contained six mice. The mice were administered
1000 mg/kg BrdUrd i.p. and 60 mg/kg pimonidazole
i.p. (Hypoxyprobe-1 Kit, Chemicon International Inc.,
Temecula, CA, USA) and euthanized 1 h later. Five
minutes prior to carbon dioxide euthanasia and
tumor harvest, the mice were administered 50 μL of
0.6 mg/mL DiOC7(3) in 25 % DMSO. Tumors were
then excised, weighed, and immediately frozen.
Immunohistochemistry. Group 1: DiOC7(3), CD31,
pimonidazole, and BrdUrd
Prior to immunostaining, the slides were imaged for
DiOC7(3) tissue fluorescence to visualize blood flow.
Cryosections were fixed in a 1:1 mixture of acetone-
methanol for 10 min at room temperature. Vasculature
was stained using a 1:400 dilution of rat-anti-CD31 (BD
553370) and 1:200 fluorescent Alexa 488 anti-rat sec-
ondary (Invitrogen, Burlington, ON, CA). Hypoxia was
detected via bound pimonidazole adducts using a 1:500
polyclonal rabbit anti-pimonidazole (Hypoxyprobe) and
a 1:200 Alexa 546 anti-rabbit secondary. Cellular DNA
was counterstained with Hoechst 33342. The slides
were imaged for fluorescence and then transferred to
distilled water for 10 min and then treated with 2 M
HCl at room temperature for 1 h followed by
neutralization for 5 min in 0.1 M sodium borate. The
slides were then washed in distilled water and transferred
to a PBS (phosphate buffered saline) bath. BrdUrd
incorporated into DNA was detected using a 1:200
dilution of monoclonal mouse anti-BrdUrd (clone BU33)
followed by 1:200 Alexa 647 anti-rabbit secondary.
Immunohistochemistry. Group 2: DiOC7(3), CD31, and HIF1-α
Cryosections were fixed in a 1:1 mixture of acetone-
methanol for 10 min at room temperature. Vasculature
was stained using a 1:400 dilution of rat-anti-CD31
(BD 553370) and 1:200 fluorescent Alexa 546 anti-rat
secondary (Invitrogen, Burlington, ON, CA). HIF1-α
was detected using a 1:500 dilution of a rabbit anti-
HIF1-α antibody (Cayman, 10006421) detected via a
1:200 Alexa 647 anti-rabbit secondary. Cellular DNA
was counterstained with Hoechst 33342.
Image acquisition
The imaging system consists of a robotic fluorescence
microscope (Zeiss Axioimager Z1, Oberkochen, Germany),
a cooled, monochrome CCD camera (Retiga 4000R,
QImaging, Vancouver, BC, Canada), a motorized slide
loader and x-y stage (Ludl Electronic Products, Hawthorne,
NY, USA), and customized ImageJ software (public do-
main program developed at the US National Institutes
of Health, available at http://rsb.info.nih.gov/ij/) run-
ning on a Macintosh computer (Apple, Cupertino, CA,
USA). The system allows tiling of adjacent microscope
fields of view. Using this system, images of entire
tumor cryosections 1–3 cm2 were captured at a reso-
lution of 0.75 μm/pixel.
Image analysis: tumor mapping
Using NIH-ImageJ and user-supplied algorithms, images
were overlaid and the areas of necrosis and staining arti-
facts were manually removed. On the fluorescence images,
CD31-, BrdUrd-, and HIF1-α-positive regions were identi-
fied using a fixed threshold. For CD31, areas less than
9 μm2 in size were considered artifacts and automatically
removed from the analysis. Average HIF1-α-positive stain-
ing and average pimonidazole/HIF1-α intensity were cal-
culated from the images of the entire tumor sections
following removal of the necrotic regions and tissue arti-
facts (folds, tears, debris, etc). The fraction of the CD31
vessels that were positive for DiOC7 was calculated based
on a 50 % coverage by area of each CD31 object. Pimoni-
dazole profiles in relation to tumor vasculature were
calculated by measuring the distance from each point in
the tissue to the nearest CD31-positive object and noting
the pimonidazole intensity at that point. This data was
then tabulated so as to determine the average pimonida-
zole staining intensity of all pixels found at each distance
to a blood vessel.
Statistical methods
Statistical analysis was conducted using GraphPad Prism
(La Jolla, CA) using one-way ANOVA tests. The signifi-
cance of differences between multiple groups was com-
pared using a Bonferroni post-test analysis.
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